Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial

Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial - Effect of PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitor on long term outcomes in patients with acute myocardial infarction: multicenter randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028730

Enrollment

180

Registered

2017-09-04

Start date

2017-09-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

As a control group, receive standard treatment, including 2 mg of pitavastatin. As a PCSK 9 inhibitor group, in addition to standard treatment, including 2 mg of pitavastatin, a PCSK9 inhibitor (Ebolo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute myocardial infarction patients who succeeded in coronary intervention treatment within 24 hours after onset of symptoms

Exclusion criteria

Exclusion criteria: cardiogenic shock, dialysis cases, cardiopulmonary arrest, severe liver disease, active malignancy, Unable to ingest statins, patients using PCSK9 inhibitors, patients with side effects on PCSK9 inhibitors in the past , Participating in another trial, a patient who is pregnant or has a possibility of pregnancy, a patient judged inappropriate by another doctor

Design outcomes

Primary

Measure	Time frame
Progression of coronary lesion after 8 months (QCA, with or without rapid progression)	—

Secondary

Measure	Time frame
Cardiovascular death, non-fatal myocardial infarction, stroke, and intervention for de novo coronary lesions	—

Countries

Japan

Contacts

Public ContactMasayuki Doi

Kagawa Prefectural Central Hospital Cardiology

mdoimd@gmail.com087-811-3333

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026